Second malignancies after breast cancer: the impact of different treatment modalities

YM Kirova*,1, Y De Rycke2, L Gambotti2, J-Y Pierga3, B Asselain2 and A Fourquet1 for the Institut Curie Breast Cancer Study Group

1Department of Radiation Oncology, Institut Curie, Paris, France; 2Department of Biostatistics, Institut Curie, Paris, France; 3Department of Medical Oncology, Institut Curie, Paris, France

Treatment for non-metastatic breast cancer (BC) may be the cause of second malignancies in long-term survivors. Our aim was to investigate whether survivors present a higher risk of malignancy than the general population according to treatment received. We analysed data for 16 705 BC survivors treated at the Curie Institute (1981–1997) by either chemotherapy (various regimens), radiotherapy (high-energy photons from a 60Co unit or linear accelerator) and/or hormone therapy (2–5 years of tamoxifen). We calculated age-standardized incidence ratios (SIRs) for each malignancy, using data for the general French population from five regional registries. At a median follow-up 10.5 years, 709 patients had developed a second malignancy. The greatest increases in risk were for leukaemia (SIR: 2.07 (1.52–2.75)), ovarian cancer (SIR: 1.6 (1.27–2.04)) and gynaecological (cervical/endometrial) cancer (SIR: 1.6 (1.34–1.89); P<0.0001). The SIR for gastrointestinal cancer, the most common malignancy, was 0.82 (0.70–0.95; P<0.007). The increase in leukaemia was most strongly related to chemotherapy and that in gynaecological cancers to hormone therapy. Radiotherapy alone also had a significant, although lesser, effect on leukaemia and gynaecological cancer incidence. The increased risk of sarcomas and lung cancer was attributed to radiotherapy. No increased risk was observed for malignant melanoma, lymphoma, genitourinary, thyroid or head and neck cancer. There is a significantly increased risk of several kinds of second malignancy in women treated for BC, compared with the general population. This increase may be related to adjuvant treatment in some cases. However, the absolute risk is small.

British Journal of Cancer (2008) 98, 870 – 874. doi:10.1038/sj.bjc.6604241 www.bjcancer.com

Published online 12 February 2008

© 2008 Cancer Research UK

Keywords: breast cancer; second malignancies; second malignant neoplasms; radiotherapy; chemotherapy; hormone therapy; long-term risk

The overall survival rate of patients with early advanced breast cancer (BC) has increased over the years largely because adjuvant therapy, whether chemotherapy, radiotherapy or hormone therapy, has helped prevent local and distant failures (Fox, 1979; Jones and Raghavan, 1993; EBCTCG, 2005). Second malignancies that occur in long-term survivors may be due to sporadic cancers that would have occurred anyway, environmental or genetic factors (Klijn et al, 1997; Schrag et al, 1997; Turner et al, 1999; Meijers-Heijboer et al, 2000; Pierce et al, 2000, 2003; Stoppa-Lyonnet et al, 2000; Galper et al, 2002; Kauff et al, 2002; Pierce, 2002; Robson, 2002; Seynaeve et al, 2004; Kirova et al, 2005a,b, 2006a; Laki et al, 2007), or BC treatment (Neugut et al, 1993; Inskip et al, 1994; Ahsan and Neugut, 1998; Karlsson et al, 1998; Kirova et al, 1998, 2005a,b, 2007; Obédian et al, 2000; Rubino et al, 2000; Scholl et al, 2001; Shousha et al 2001; Yap et al, 2002, 2005; Deutsch et al, 2003; Zablotska and Neugut, 2003; Zablotska et al, 2005; Mellemjaer et al, 2006).

The aim of this study was to estimate the risk of a second malignancy after adjuvant treatment for BC in a homogeneous cohort of patients from a single institution. The observed incidence of second malignancies in these BC patients was compared with the expected age-adjusted number of new cases in the general population of French women as given by data from five regional registries (Remontet et al, 2003).

PATIENTS AND METHODS

We analysed data for 16 705 consecutive patients with non-metastatic BC who were treated at the Institut Curie between 1981 and 1997. The data, including treatments, were entered prospectively into the Institute’s BC database set up in 1981 (Salmon et al, 1997). Chemotherapy regimens in adjuvant and neoadjuvant setting varied over time based on CMF (cyclophosphamide, methotrexate and 5-fluorouracile), FAC (5-fluorouracile, adriamycine and cyclophosphamide) or FEC (epirubicin). All patients received alkylating agents and the majority received anthracyclins. Hormonal therapy consisted mostly of 2–5 years of administration
of tamoxifen. Patients who underwent radiotherapy received high-energy photons produced by a 60Co unit or linear accelerator, as previously described, either as sole treatment or pre- or post surgery (Fourquet et al, 1991; Campana et al, 2005; Kirova et al, 2006b). Follow-up included a six-monthly clinical examination and a once-yearly mammogram for 5 years, and then a once-yearly clinical examination and a unilateral or bilateral mammogram for the lifetime of every patient. All follow-up data were entered into the database. At 5 years, 5% of patients were lost to follow-up and at 10 years, 8% were lost to follow-up.

We recorded clinical and primary tumour variables, radiation history and irradiation fields, for all patients with histologically confirmed second malignancies. Second malignancies included all first cancers occurring after treatment of the primary BC, but excluded contralateral BC.

Statistical analysis

We first calculated Kaplan–Meier cumulative incidence and the 10-year risk of developing each type of second malignancy (Kaplan and Meier, 1958). The observed crude incidence rates in the entire patient population (cases per 100 000 person-years) were then compared with the expected incidence in the general population of French women as given by age-standardized data from five regional registries (Remontet et al, 2003), and a standardized incidence ratio (SIR) was calculated for each malignancy. We then calculated the SIRs for the highest-risk malignancies according to the adjuvant treatment the patients had received to study the impact of treatment on risk. The Poisson regression model was used to adjust the analysis. The data were analysed using ‘S Plus 6.2, Insightful Corp.’ software.

RESULTS

Median follow-up was 10.5 years (range 0.2–24 years). Median patient age at the time of BC diagnosis was 56.2 years. Of the total population of 16 705 patients, 13 472 (80.6%) received radiation therapy, 2347 (17.4%) underwent mastectomy followed by radiotherapy, 8596 (63.8%) lumpectomy then radiotherapy, and 2529 (18.8%) were treated by radiotherapy alone. A total of 4528 patients (27.1%) received chemotherapy (14.3% chemotherapy alone; 12.8% chemotherapy plus hormone therapy) and 16.5% received hormone therapy alone. Overall, 9414 patients (56.4%) did not receive any systemic adjuvant therapy. The number of patients receiving different treatment combinations is given in Table 1.

By 10.5 years of median follow-up, 709 patients had developed a second malignancy. Table 2 gives the cumulative incidence of second malignancies 10.5 years after BC in the study population by decreasing order of incidence. Gastrointestinal (GI) cancer was the most common cancer, followed by gynaecological cancer (cervical and endometrial) and ovarian cancer. Table 3 compares the observed crude incidence in patients and the incidence in the general population of French women. Of all the malignancies, only

leukaemia, ovarian and other gynaecological cancers (cervical and endometrial), and GI tumours, showed a significantly higher incidence in patients than in the general population. Among the 74 patients with histologically confirmed primary ovarian cancer, 13 underwent genetic testing because they presented a familial history of BC or ovarian cancer and, of these 13 patients, 10 were carriers of BRCA mutations (9 of BRCA1, 1 of BRCA2).

The extent to which the different treatments constituted risk factors for a second malignancy is shown in Table 4. Chemotherapy was the most important risk factor for leukaemia and highly significantly increased the risk of this disease. Radiotherapy was a much less significant risk factor. Both hormone treatment and radiotherapy were significant risk factors for gynaecological cancers. The SIR of ovarian cancer was threefold higher in patients who had received radiotherapy plus chemotherapy than in patients receiving no adjuvant therapy. The combination treatment was a highly significant risk factor. Chemotherapy alone had no significant effect maybe because of the small number of events and lack of statistical power. We found no relationship between GI tumours and BC treatment (not shown).

DISCUSSION

To our knowledge, this is the largest retrospective study from a single institution on second malignancies and one of the first to attempt to relate the incidence and risk of a second malignancy in patients with non-metastatic BC to the expected number of cases in the general population of women of the same age, after stratifying patients by treatment received (Rubino et al, 2000). Patients treated for BC showed increased risk of leukaemia, ovarian cancer, and gynaecological cancers, and a slightly enhanced risk of GI cancers, in addition to the well-known risk of developing sarcomas (Kirova et al, 2005b) and lung cancer after radiation therapy (Kirova et al, 2007). The increase in leukaemia was most strongly related to chemotherapy (alkylating agents) and that in gynaecological cancers to hormone therapy (the main treatment was tamoxifen). Radiation therapy alone also had a significant, but lesser, effect found only in comparison with the general population (Rubino et al, 2000).

There was no difference between irradiated and non-irradiated patients with regard to leukaemia risk (Kirova et al, 2007), but there was a significant difference between our patients and the general population. Such a difference has already been noted and has been related to the use of adjuvant chemotherapy (7, 13, 19, 34; Rubino et al, 2000). At the Institut Gustave Roussy, the overall SIR for leukaemia was 3.1 (95% confidence interval (CI): 1.7–5.0) in

| Table 2 Ten-year cumulative incidence of second malignancy (Kaplan–Meier estimates) |
|-----------------------------------------------|
|          | n  | (%) | 95% CI          |
|-----------------------------------------------|
| Gastrointestinal                        | 182 |  11.5 | 9.5–13.4        |
| Gynaecological*                         | 132 |  8.6 | 6.9–10.2        |
| Ovary                                     | 74  |  5.0 | 3.8–6.3         |
| Lung                                      | 58  |  3.7 | 2.6–4.9         |
| Leukaemia                                 | 47  |  3.3 | 2.3–4.3         |
| Melanoma                                  | 37  |  2.8 | 1.8–3.8         |
| Lymphoma                                  | 41  |  2.6 | 1.7–3.5         |
| Genitourinary                             | 41  |  2.2 | 1.4–3.0         |
| Sarcoma                                   | 34  |  2.1 | 1.3–3.0         |
| Others                                    | 25  |  1.6 | 0.8–2.3         |
| Thyroid                                   | 20  |  1.4 | 0.7–2.1         |
| Head and neck                             | 18  |  1.1 | 0.5–1.6         |
| Total                                     | 709 |  45.0| 41.2–48.7       |

Abbreviation: CI = confidence interval. *Cervical and endometrial.
Clinical Studies

Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. 

British Journal of Cancer (2008) 98

Ahsan H, Neugut AI (1998) Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Int Med 128: 114 – 117 Blamey RW, Mackay J, Macmillan D (2004) EUSOMA guidelines on the management of familial breast cancer risk. Eur J Cancer 2: 155 (abstract)

REFERENCES

Table 3 Crude cancer incidence rates in patients and in the general population of French women (by decreasing order of SIR)

| Second malignancy          | Patients Crude incidence rates 100 000 PY | General population SIR | 95% CI  | P       |
|---------------------------|------------------------------------------|-------------------------|---------|---------|
| Leukaemia                 | 30.4                                     | 8.7                     | 2.07    | 1.52 – 2.75 | <0.0001 |
| Ovarian                   | 47.6                                     | 14.9                    | 1.6     | 1.27 – 2.04 | <0.0001 |
| Gynaecological            | 86.0                                     | 28.0                    | 1.6     | 1.34 – 1.89 | <0.0001 |
| Lung                      | 37.5                                     | 15.2                    | 1.2     | 0.91 – 1.55 | 0.16    |
| Malignant melanoma        | 23.9                                     | 13.8                    | 1.07    | 0.76 – 1.48 | 0.67    |
| Lymphoma                  | 26.9                                     | 16.6                    | 0.95    | 0.68 – 1.29 | 0.76    |
| Genitourinary             | 26.6                                     | 15.8                    | 0.89    | 0.64 – 1.20 | 0.44    |
| Thyroid                   | 12.9                                     | 9.6                     | 0.87    | 0.53 – 1.35 | 0.54    |
| Gastrointestinal          | 119.1                                    | 15.9                    | 0.82    | 0.70 – 0.95 | 0.007   |
| Head and neck             | 11.6                                     | 9.1                     | 0.64    | 0.38 – 1.01 | 0.06    |
| Sarcoma                   | 22.3                                     | NA†                     | —       | —       |         |

4416 BC patients and 2.1 (95% CI: 1.1 – 3.5) in the subpopulation of 416 patients receiving chemotherapy (Rubino et al, 2000).

Our observation of an increased risk of ovarian cancer confirms previous findings (Easton et al, 1993; Breast Cancer Linkage Consortium, 1997; Fisher et al, 1998; Chappuis et al, 2000; Haber, 2002; Haffty et al, 2002; Kauff et al, 2003; Pierce et al, 2003; Blamey et al, 2004) and suggests that these patients may have a familial predisposition to BC and ovarian cancer. Although we tested 13 of 74 patients with ovarian cancer for BRCA1 or BRCA2 mutations and found a mutation in 10 of the 13 patients with familial cancer, this result is not representative of the whole population of patients. We included patients as from 1981, but only began genetic testing in the early nineties. The increased risk of endometrial cancer might be due to tamoxifen use, as shown by others (Ewertz and Mouridsen, 1983; Brenner et al, 1993; Volk and Pompe-Kirn, 1997). Confirmation of this would need distinguishing different types of hormone therapy (anti-estrogens, anti-aromatase) from surgical hysterectomy and radiation-induced castration. 

No relationship between GI cancers and different treatment modalities was observed. This and our previous study did not find increased incidence of oesophageal cancers, related to the radiation treatment (Kirova et al, 2007).

A major strength of our study is the large volume of individual patient data from a single institution. This differentiates it from epidemiological studies that lack individual data on patient treatment and from most single-institution series that are much smaller. However, despite the large number of patients and long follow-up (10.5 years), the incidence of second malignancies may nevertheless remain underestimated because of the long latency period of some tumours.

In conclusion, this study has confirmed an increased risk of second malignancies in women treated for BC, compared with the general population. This increase may be related to adjuvant treatment in some cases. However, the absolute risk is small and the influence of other predisposing factors, such as family history, will need to be investigated in a prospective study.

ACKNOWLEDGEMENTS

We acknowledge Chantal Gautier and Muriel Belotti for help in data management. This study did not receive any grant support.

Conflict of interest
None.

REFERENCES

Ahsan H, Neugut AI (1998) Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Int Med 128: 114 – 117 Blamey RW, Mackay J, Macmillan D (2004) EUSOMA guidelines on the management of familial breast cancer risk. Eur J Cancer 2: 155 (abstract)

Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349: 1505 – 1510

Brenner H, Siegle S, Stegmaier C, Ziegler H (1993) Second primary neoplasms following breast cancer in Saarland, Germany, 1968 – 1987. Eur J Cancer 29: 1410 – 1414

Campana F, Kirova YM, Rosenwald JC, Dendale R, Vilcoq JR, Dreyfus H, Fourquet A (2005) Breast radiotherapy in the lateral decubitus position – a technique to prevent lung and heart irradiation. Int J Radiat Oncol Biol Phys 61: 1348 – 1354
Kirova YM, Vilcoq JR, Asselain B, Sastre-Garaux E, Fournet A (2005b) Radiation-induced sarcomas (RIS) following radiotherapy for breast cancer: a large-scale single institution review. *Cancer* **104**: 856 – 863
Klijn JG, Janin N, Cortés-Funes H, Colomer R (1997) Should prophylactic surgery be used in women at high risk of breast cancer? *Eur J Cancer* **33**: 2149 – 2159
Laki F, Kirova YM, This P, Planche C, Asselain B, Sastre X, Stoppa-Lyonnet D, Salmon R (2007) Prophylactic salpingo-oophorectomy in a series of 89 women carrying a *BRCA1* or *BRCA2* mutation. *Cancer* **109**: 1784 – 1790
Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, Dukel D, Devilee P, van den Ouweland AM, van Geel AN, Klijn JG (2000) Presymptomatic DNA testing and prophylactic surgery in families with a *BRCA1* or *BRCA2* mutation. *Lancet* **355**: 2015 – 2020.
Mellermajer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Andersen A, Brewer DH, Pukkala E, McBride ML, Kliever EV, Tonita JM, Kee Seng, C, Pompe-Kim V, Martos C, Jonasson JG, Bolfetta P, Brennan P (2006) Risk of second cancer among women with breast cancer. *Int J Cancer* **118**: 2285 – 2292
Neugut AI, Robinson E, Lee WC, Murray T, Karwowski K, Katcher GJ (1993) Lung cancer after radiation therapy for breast cancer. *Cancer* **71**: 3054 – 3057
Obedian E, Fischer DB, Haffty BG (2000) Second malignancies after treatment of early stage breast cancer. Lumpectomy and radiation therapy. *Hematol Oncol* **18**: 2406 – 2412
Pierce L, Levin A, Rebbeck T (2003) Ten-year outcome of breast-conserving surgery and radiotherapy in women with breast cancer and germline *BRCA1*/*2* mutations: results from an international collaboration. *Breast Cancer Res Treat* **82**: S7 (5), (abstr).
Pierce L (2002) Radiotherapy for breast cancer in *BRCA1*/*BRCA2* carriers: clinical issues and management dilemmas. *Semin Radiat Oncol* **12**: 352 – 361
Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, Gaffney D, Solin L, Nixon A, Garber J, Berg C, Isaacs C, Heinnamon R, Olopade OI, Haffty B, Weber BL (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline *BRCA1*/*2* mutations. *J Clin Oncol* **18**: 3360 – 3369
Remontet L, Buemi A, Velten M, Jugla E, Estève J (2003) Evolution of the incidence and of the mortality of cancer in France de 1978 à 2000
Robson ME (2002) Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. *Cancer Control* **9**: 457 – 465
Rubino C, de Vathaire F, Diel AO, Shamsaldin A, G Lè M (2000) Increased risk of second cancers following breast cancer: role of the initial treatment. *Breast Cancer Res Treat* **61**: 183 – 195
Salmon RJ, Asselain B, Le Gal M (1997) Twelve years experience of breast cancer at the Institut Curie: improvement of survival and value of screening mammographies. *Breast* **6**: 202 – 205
Scholl R, Reis ED, Žouhair A, Cherevishn I, Givel JC, Gillet M (2001) Esophageal cancer as a second primary tumor after breast radiotherapy. *Am J Surg* **182**: 476 – 480
Schrag D, Kunz TM, Garber JE, Weeks JC (1997) Decision analysis – effects of prophylactic mastectomy and oophorectomy on life expectancy among women with *BRCA1* or *BRCA2* mutations. *N Engl J Med* **336**: 1465 – 1471
Seynaeve C, Verhoog LC, van de Bosch LM, van Geel AN, Menke-Plummers M, Meijers-Heijboer EJ, van den Ouweland AM, Wagner A, Creutzberg CL, Niermeijer MF, Klijn JG, Brekelmans CT (2004) Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. *Eur J Cancer* **40**: 1150 – 1158
Shossa S, Fawcett A, Luqmani YA, Theodorou N (2001) Multifocal squamous cell carcinoma of the oesophagus following radiotherapy for bilateral breast cancer. *J Clin Pathol* **54**: 718 – 720
Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstuyn E, Clough KB, Magdelénat H, Pouillard P, Vincent-Salomon A, Fournet A, Asselain B (2000) Familial invasive breast cancers: worse outcome related to *BRCA1* mutations. *J Clin Oncol* **18**: 4053 – 4059
Turner BC, Harrod D, Matloff E, Smith T, Gumbs A, Beinfeld M, Ward B, Skolnick M, Glazer PM, Thomas A, Haffty BG (1999) *BRCA1*/*BRCA2* germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with *BRCA1*/*BRCA2* mutations. *J Clin Oncol* **17**: 3017 – 3024
Volk N, Pompe-Kirn V (1997) Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 8: 764–770
Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK, Hamre M (2002) Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 52: 1231–1237
Zablotska LB, Chak A, Das A, Neugut AI (2005) Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am J Epidemiol 161: 330–337
Zablotska LB, Neugut AI (2003) Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 97: 1404–1411